Pendopharm, a division of Pharmascience, said it has signed an exclusive distribution agreement with Denmark-based biopharmaceutical company Ascendis Pharma A/S ( ASND ). Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransCon PTH in Canada. Financial terms of the agreement are not disclosed.
Source: Press Release More on Ascendis Pharma An Update On Ascendis Pharma's Path To Profitability Ascendis Pharma says FDA has delayed TransCon PTH review Ascendis Pharma reports Q1 results Seeking Alpha’s Quant Rating on Ascendis Pharma.
